S-phase fraction and breast cancer - A decade of experience

Breast Cancer Research and Treatment

Volumn 51, Issue 3, 1998, Pages 255-265

  Wenger, Charlotte R ^a   Clark, Gary M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast cancer; Prognostic factor; S phase fraction

Indexed keywords

MARKER;

ASSAY; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; REVIEW; STANDARDIZATION; TECHNIQUE;

BREAST NEOPLASMS; FEMALE; FLOW CYTOMETRY; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; S PHASE;

EID: 0032443239     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006188512927     Document Type: Review

References (84)

1. Hedley DW, Rugg CA, Gelber RD: Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res 47:4729-4735, 1987
2. Dressler LG, Seamer L, Owens MA, et al: Evaluation of a modeling system for S-phase estimation in breast cancer by flow cytometry. Cancer Res 47:5294-5302, 1987
3. Hedley DW, Clark GM, Cornelisse CJ, et al: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 14:482-485, 1993
4. ASCO Tumor Marker Panel: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843-2877, 1996
5. Dressler LG, Seamer LC, Owens MA, et al: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61:420-427, 1988
6. Kallioniemi O-P, Blanco G, Alavaikko M, et al: Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer. Cancer 62:2183-2190, 1988
7. Clark GM, Dressler LG, Owens MA, et al: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627-633, 1989
8. Eskelinen MJ, Pajarinen P, Collan Y, et al: Relationship between DNA ploidy and survival in patients with primary breast cancer. Br J Surg 76:830-834, 1989
9. Hatschek T, Fagerberg G, Stål O, et al: Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program. Cancer 64:1074-1081, 1989
10. Stål O, Wingren S, Carstensen J, et al: Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. Eur J Cancer Clin Oncol 25:301-309, 1989
11. Toikkanen S, Joensuu H, Klemi P: The prognostic significance of nuclear DNA content in invasive breast cancer - a study with long-term follow-up. Br J Cancer 60:693-700, 1989
12. O'Reilly SM, Camplejohn RS, Millis RR, et al: Proliferative activity, histological grade and benefit from adjuvant chemotherapy in node positive breast cancer. Eur J Cancer 26:1035-1038, 1990
13. O'Reilly SM, Camplejohn RS, Barnes DM, et al: DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 61:671-674, 1990
14. O'Reilly SM, Camplejohn RS, Barnes DM, et al: Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol 8:2040-2046, 1990
15. Sigurdsson H, Baldetorp B, Borg Å, et al: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322:1045-1053, 1990
16. Toikkanen S, Joensuu H: Long-term prognosis of scar and non-scar cancers of the breast. APMIS 98:1033-1038, 1990
17. Winchester DJ, Duda RB, August CZ, et al: The importance of DNA flow cytometry in node-negative breast cancer. Arch Surg 125:886-889, 1990
18. Anbazhagan R, Gelber RD, Bettelheim R, et al: Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 2:47-53, 1991
19. Ewers SB, Attewell R, Baldetorp B, et al: Prognostic potential of flow cytometric S-phase and ploidy prospectively determined in primary breast carcinomas. Breast Cancer Res Treat 20:93-108, 1991
20. Fisher B, Gunduz N, Costantino J, et al: DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer 68:1465-1475, 1991
21. Olsson H, Ranstam J, Baldetorp B, et al: Proliferation and DNA ploidy in malignant breast tumors in relation to early oral contraceptive use and early abortions. Cancer 67:1285-1290, 1991
22. O'Reilly SM, Barnes DM, Camplejohn RS, et al: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63:444-446, 1991
23. Toikkanen SP, Kujari HP, Joensuu H: Factors predicting late mortality from breast cancer. Eur J Cancer 27:586-591, 1991
24. Aaltomaa S, Lipponen P, Papinaho S, et al: Nuclear morphometry and DNA flow cytometry as prognostic factors in female breast cancer. Eur J Surg 158:135-141, 1992
25. Baldetorp B, Fernö M, Fallenius A, et al: Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry 13:577-585, 1992
26. Clark GM, Mathieu M-C, Owens MA, et al: Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10:428-432, 1992
27. Eskelinen M, Lipponen P, Papinaho S, et al: DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer 51:555-561, 1992
28. Ewers S-B, Attewell R, Baldetorp B, et al: Flow cytometry DNA analysis and prediction of loco-regional recurrences after mastectomy in breast cancer. Acta Oncologica 31:733-740, 1992
29. Ewers S-B, Attewell R, Baldetorp B, et al: Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinomas - a 10 year survival study. Breast Cancer Res Treat 24:115-126, 1992
30. Fernö M, Baldetorp B, Ewers S-B, et al: One or multiple samplings for flow cytometric DNA analyses in breast cancer - prognostic implications? Cytometry 13:241-249, 1992
31. Haffty BG, Toth M, Flynn S, et al: Prognostic value of DNA flow cytometry in the locally recurrent, conservatively treated breast cancer patient. J Clin Oncol 10:1839-1847, 1992
32. Joensuu H, Alanen K, Falkmer UG, et al: Effect of DNA ploidy classification on prognosis in breast cancer. Int J Cancer 52:701-706, 1992
33. Joensuu H, Toikkanen S: Identification of subgroups with favorable prognosis in breast cancer. Acta Oncologica 31:293-301, 1992
34. Johnson H Jr, Masood S, Belluco C, et al: Prognostic factors in node-negative breast cancer. Arch Surg 127:1386-1391, 1992
35. Klemi PJ, Joensuu H, Toikkanen S, et al: Aggressiveness of breast cancers found with and without screening. Br Med J 304:467-469, 1992
36. Lipponen P, Eskelinen M, Papinaho S, et al: Sex steroid receptors, S-phase fraction and DNA ploidy as determinants of the risk of relapse and death of female breast cancer. Anticancer Res 12:677-682, 1992
37. Lipponen P, Papinaho S, Eskelinen M, et al: DNA ploidy, S-phase fraction and mitotic indices as prognostic predictors of female breast cancer. Anticancer Res 12:1533-1538, 1992
38. Stål O, Brisfors A, Carstensen J, et al: Interrelations between cellular DNA content, S-phase fraction, hormone receptor status and age in primary breast cancer. A series of 1,342 consecutively detected tumors. South-East Sweden Breast Cancer Group. Acta Oncologica 31:283-292, 1992
39. Stål O, Brisfors A, Carstensen J, et al: Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. The South-East Sweden Breast Cancer Group. Int J Cancer 51:28-33, 1992
40. Stål O, Carstensen J, Hatschek T, et al: Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients. Br J Cancer 66:706-711, 1992
41. Stanton PD, Cooke TG, Oakes SJ, et al: Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. Br J Cancer 66:925-929, 1992
42. Aaltomaa S, Lipponen P, Papinaho S, et al: Proliferating-cell nuclear antigen (PC10) immunolabelling and other proliferation indices as prognostic factors in breast cancer. J Cancer Res Clin Oncol 119:288-294, 1993
43. Brooks SA, Leathem AJC, Camplejohn RS, et al: Markers of prognosis in breast cancer - the relationship between binding of the lectin HPA and histological grade, SPF, and ploidy. Breast Cancer Res Treat 25:247-256, 1993
44. Clark GM, Wenger CR, Beardslee S, et al: How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 71:2157-2162, 1993
45. Merkel DE, Winchester DJ, Goldschmidt RA, et al: DNA flow cytometry and pathologic grading as prognostic guides in axillary lymph node-negative breast cancer. Cancer 72:1926-1932, 1993
46. Stål O, Dufmats M, Hatschek T, et al: S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 11:1717-1722, 1993
47. Wenger CR, Beardslee S, Owens MA, et al: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28:9-20, 1993
48. Wingren S, Stål O, Carstensen J, et al: S-phase determination of immunoselected cytokeratin-containing breast cancer cells improves the prediction of recurrence. Breast Cancer Res Treat 29:179-187, 1993
49. Ahlgren J, Stål O, Westman G, et al: Prediction of axillary lymph node metastases in a screened breast cancer population. South-East Sweden Breast Cancer Group. Acta Oncologica 33:603-608, 1994
50. Balslev I, Christensen IJ, Rasmussen BB, et al: Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. Int J Cancer 56:16-25, 1994
51. Chadha M, Chabon AB, Friedmann P, et al: Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis. Cancer 73:350-353, 1994
52. Elledge RM, Clark GM, Chamness GC, et al: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86:705-712, 1994
53. Gasparini G, Boracchi P, Verderio P, et al: Cell kinetics in human breast cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 57:822-829, 1994
54. Leivonen M, Krogerus L, Nordling S: DNA analysis in advanced breast cancer. Cancer Detection Prevention 18:87-96, 1994
55. Meyer JS, Province MA: S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer 74:2287-2299, 1994
56. Mink D, von Tongelen B, Villena-Heinsen C, et al: Breast cancer and prognostic factors. Tumour size, degree of differentiation, proliferation kinetics and expression of steroid hormone receptors. Eur J Gynaec Oncol 15:424-436, 1994
57. Pedersen L, Larsen JK, Christensen IJ, et al: DNA ploidy and S-phase fraction in medullary carcinoma of the breast - a flow cytometric analysis using archival material. Breast Cancer Res Treat 29:297-306, 1994
58. Ravdin PM, De Laurentiis M, Vendely T, et al: Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 86:1771-1775, 1994
59. Stål O, Carstensen JM, Wingren S, et al: Relationship of DNA ploidy and S-phase fraction to survival after first recurrence of breast cancer. Acta Oncologica 33:423-429, 1994
60. Stål O, Skoog L, Rutqvist LE, et al: S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 70:1258-1262, 1994
61. Stål O, Sullivan S, Sun X-F, et al: Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Cytometry 16:160-168, 1994
62. Wingren S, Stål O, Sullivan S, et al: S-phase fraction after gating on epithelial cells predicts recurrence in node-negative breast cancer. Int J Cancer 59:7-10, 1994
63. Brower ST, Tartter PI, Ahmed S, et al: Proliferative indices and oncoprotein expression in benign and malignant breast biopsies. Ann Surg Oncol 2:416-423, 1995
64. Camplejohn RS, Ash CM, Gillett CE, et al: The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre. Br J Cancer 71:140-145, 1995
65. Cook DL, Weaver DL: Comparison of DNA content, S-phase fraction, and survival between medullary and ductal carcinoma of the breast. Am J Clin Pathol 104:17-22, 1995
66. Fernando IN, Powles TJ, Dowsett M, et al: Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry. Virchows Archiv 426:155-161, 1995
67. Fernö M, Baldetorp B, Bendahl P-O, et al: Recurrence-free survival in breast cancer improved by adjuvant tamoxifen - especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res Treat 36:23-34, 1995
68. Hietanen P, Biomqvist C, Wasenius V-M, et al: Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer 71:1029-1032, 1995
69. Kute TE, Quadri Y, Muss H, et al: Flow cytometry in node-positive breast cancer: Cancer and Leukemia Group B protocol 8869. Cytometry 22:297-306, 1995
70. Ottesen GL, Christensen IJ, Larsen JK, et al: DNA aneuploidy in early breast cancer. Br J Cancer 72:832-839, 1995
71. Pfisterer J, Kommoss F, Sauerbrei W, et al: DNA flow cytometry in node-positive breast cancer. Prognostic value and correlation with morphologic and clinical factors. Analyt Quant Cytol Histol 17:406-412, 1995
72. Rosanelli GPH, Steindorfer P, Wirnsberger GH, et al: Mutant p53 expression and DNA analysis in human breast cancer: comparison with conventional clinico-pathological parameters. Anticancer Res 15:581-586, 1995
73. Bergers E, van Diest PJ, Baak JPA: Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J Clin Pathol 49:931-937, 1996
74. Chevillard S, Pouillart P, Beldjord C, et al: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77:292-300, 1996
75. Dittadi R, Calderazzo F, Cabrelle A, et al: c-erbB-2/neu protein expression, DNA ploidy and S phase in breast cancer. Cell Prolif 29:403-412, 1996
76. Gaffney EVI, Venz-Williamson TL, Hutchinson G, et al: Relationship of standardized mitotic indices to other prognostic factors in breast cancer. Arch Pathol Lab Med 120:473-477, 1996
77. Marcus JN, Watson P, Page DL, et al: Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996
78. Romero H, Schneider J, Burgos J, et al: S-phase fraction identifies high-risk subgroups among DNA-diploid breast cancers. Breast Cancer Res Treat 38:265-275, 1996
79. Dettmar P, Harbeck N, Thomssen C, et al: Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 75:1525-1533, 1997
80. Peiró G, Lerma E, Climent MA, et al: Prognostic value of S-phase fraction in lymph-node-negative breast cancer by image and flow cytometric analysis. Mod Pathol 10:216-222, 1997
81. Wyss-Desserich MT, Caduff-Joos R, Wyss P, et al: Premenopausal node-negative breast cancer: may adjuvant chemotherapy be indicated by the analysis of nuclear DNA dynamics? Breast Cancer Res Treat 42:253-263, 1997
82. Clark GM: Prognostic and predictive factors for breast cancer. Breast Cancer 2:79-89, 1995
83. Hutchins L, Green S, Ravdin P, et al: CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102. Proc Am Soc Clin Oncol 17:1a (abs 2), 1998
84. Clark GM: Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott-Raven, Philadelphia, 1996, pp 461-485